FOXP3+ regulatory T cells: Current controversies and future perspectives

Area of Science:

• Immunology
• Cell Biology

Background:

• Regulatory T cells (Treg) are vital for immune homeostasis, preventing autoimmunity and transplant rejection, but can also facilitate tumor immune evasion.
• Translating Treg research from mouse models to human applications is hindered by difficulties in precisely defining human Treg populations using traditional markers like CD25.
• Understanding Treg biology is critical for developing immunotherapies, including Treg-based treatments for autoimmune diseases and Treg-targeted therapies for cancer.

Purpose of the Study:

• To evaluate the utility of the FOXP3 transcription factor for identifying human regulatory T cell populations.
• To review current data on FOXP3 expression in lymphomas and its implications for cancer immunology.
• To highlight the complexities and challenges in Treg research and therapeutic manipulation.

Main Methods:

• Literature review focusing on Treg identification and FOXP3 expression.
• Analysis of recent data on FOXP3 in human Treg populations and hematological malignancies.
• Synthesis of information regarding the dual role of Treg in health and disease.

Main Results:

• Contradictory findings exist regarding human Treg numbers and functions across different diseases.
• FOXP3 shows promise as a key marker for identifying Treg populations in humans.
• Malignant cells in hematological malignancies can also be targets of Treg activity, adding complexity to cancer therapy.

Conclusions:

• Accurate identification of human Treg populations, potentially via FOXP3, is essential before implementing Treg-based therapies.
• The role of Treg in cancer, particularly hematological malignancies, is complex and requires further investigation.
• Further research into Treg biology is crucial for advancing immunotherapies for autoimmune diseases and cancer.